Compare Hims and Hers Health Inc (HIMS) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Northrop Grumman Corporation — how do they compare? Hims and Hers Health Inc trades at $30.87 (market cap $6.55B), while Northrop Grumman Corporation trades at $480.06 (market cap $68.83B). The key difference: Northrop Grumman Corporation is far larger — about 10.5× Hims and Hers Health Inc's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Northrop Grumman Corporation for 81 Days on average.
| HIMS | NOC | |
|---|---|---|
Market Cap | $6.55B | $68.83B |
Volume | 14,842,814 | 1,081,989 |
Sector | Health | Industrials |
52-Week High | $62.76 | $768.02 |
52-Week Low | $14.52 | $473.46 |
Typical Hold Time | 21 Days | 81 Days |
Enterprise Value | $7.25B | $82.81B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
Northrop Grumman (NOC) trades at $480.85, up 1.56% with recent earnings beats but faces technical bearish signals. The company maintains strong fundamentals with $41.95B revenue, 10.48% net margin, and attractive valuation at 15.4 P/E. Recent news highlights both contract wins and competitive losses, including Boeing's $20B Navy fighter award.
Outlook remains positive with analyst consensus at $600.62 target (25% upside) and 54% buy ratings. Key risks include defense contract volatility and competitive pressures, while strong backlog ($104.7B) and dividend growth support long-term value. The stock offers defensive exposure to elevated defense spending cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
